FHD-286 is under clinical development by Foghorn Therapeutics and currently in Phase I for Chronic Myelomonocytic Leukemia (CMML). According to GlobalData, Phase I drugs for Chronic Myelomonocytic Leukemia (CMML) have an 82% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how FHD-286’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

FHD-286 overview

FHD-286 is under development for the treatment of relapsed/refractory acute myelocytic leukemia, relapsed/refractory chronic myelomonocytic leukemia (CMML), myelodysplastic syndrome and non-small cell lung cancer (NSCLC), prostate cancer. It is administered through oral route. The drug candidate is developed based on Gene Traffic Control (GTC) platform. It acts by targeting SMARCA2 (BRM) and SMARCA4 (BRG1). It was also under development for metastatic uveal melanoma.

Foghorn Therapeutics overview

Foghorn Therapeutics is a pharmaceutical company. The company discovers and develops novel drugs to treat cancer and other serious medical disorders. Its Gene Traffic Control Platform is a chromatin regulatory system that directs which genes our cells express and when, where and in what order. Foghorn Therapeutics products pipeline includes FHD-286 (BRM / BRG1), FHD-609 (BRD9), Selective BRM, and ARID1B. The company has developed a new approach of controlling gene expression, new insights, advanced six programs and created a discovery engine that yield’s additional targets in multiple types of cancers and other diseases. Foghorn Therapeutics is headquartered in Cambridge, Massachusetts, the US.

For a complete picture of FHD-286’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.